Long-term impact of interferon or Copaxone (Glatiramer acetate) in MS: A systematic review and meta-analysis

Image Source: ISRAELVALLEY
Read more »

Labels: Study

Estriol combined with Copaxone (glatiramer acetate) for women with relapsing-remitting MS a randomised, placebo-controlled, phase 2 trial: STUDY

Image Source: PINTEREST
Read more »

Labels: Study

A randomized trial of Aubagio (teriflunomide) added to Copaxone (glatiramer acetate) in relapsing MS

Image Source: BING
Read more »

Labels: Aubagio, Study

The Effect of Three Times a Week Copaxone (Glatiramer Acetate) on Cerebral T1 Hypointense Lesions in Relapsing-Remitting MS: STUDY

Image Source: ISRAELVALLEY

Read more »

Labels: Study

Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to Copaxone (glatiramer acetate): STUDY

ISRAELVALLEY
Read more »

Labels: Study

Tolerability and Safety of Combined Copaxone (Glatiramer Acetate) and N-Acetylcysteine in Relapsing-Remitting MS: STUDY

Image source: PREVENTDISEASE
Read more »

Labels: Study

GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of Copaxone (glatiramer acetate) 40 mg/ml three-times weekly versus 20 mg/ml daily in patients with relapsing-remitting multiple sclerosis: STUDY

Image source: PHARMAFILE
Read more »

Labels: Study

Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with Copaxone (glatiramer acetate)

Image source: MYELITETMOI
Read more »

Labels: Study

Patient experience with Copaxone (glatiramer acetate) 40 mg/1 mL three-times weekly treatment for relapsing-remitting multiple sclerosis: Results from the GLACIER extension study: STUDY

Read more »

Labels: Study

Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability: STUDY

Read more »

Labels: Study

Comparison of Relapse Rates in Multiple Sclerosis Patients Switching from Glatiramer Acetate (Copaxone) to Fingolimod (Gilenya) versus Those Remaining on Glatiramer Acetate: STUDY

Read more »

Labels: Gilenya, Study

Comparative effectiveness of Copaxone (glatiramer acetate) and interferon beta formulations in relapsing–remitting multiple sclerosis: STUDY

Read more »

Labels: Avonex, Betaseron, Rebif, Study

Impact of a switch to Gilenya (fingolimod) versus staying on Copaxone (glatiramer acetate) or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial: STUDY

Read more »

Labels: Gilenya, Study

Comparative effectiveness of Copaxone (glatiramer acetate) and interferon beta formulations in relapsing–remitting multiple sclerosis: STUDY

Read more »

Labels: Avonex, Betaseron, Rebif, Study

Impact of a switch to Gilenya (fingolimod) versus staying on Copaxone (glatiramer acetate) or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial: STUDY

Read more »

Labels: Gilenya, Study

Friday's News for Neurologists: Here's 276 New Studies from 10/1 to Friday 11/1

REGIONAL PATTERNS OF GREY MATTER ATROPHY AND MAGNETISATION TRANSFER RATIO ABNORMALITIES IN MULTIPLE SCLEROSIS CLINICAL SUBGROUPS.

CANNABINOID USE IN PROGRESSIVE INFLAMMATORY BRAIN DISEASE (CUPID) MRI SUB-STUDY.

DOES JCV ANTIBODY POSITIVITY ENCOURAGE CESSATION OF TYSABRI (NATALIZUMAB) THERAPY IN MULTIPLE SCLEROSIS?

EFFICACY AND SAFETY OF TYSABRI (NATALIZUMAB) TREATMENT FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS: INTERIM RESULTS OF THE TYSABRI(R) OBSERVATIONAL PROGRAMME IN THE UK.

A SERVICE DEVELOPMENT AUDIT OF FAMPRIDINE USE IN MS.

NEUTRALISING ANTIBODIES TO INTERFERON-BETA PREDICT CONVERSION TO SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS IN PATIENTS WITH MULTIPLE SCLEROSIS.

A DECADE OF DATA FOR THE UK MULTIPLE SCLEROSIS RISK-SHARING SCHEME.

PATTERNS OF COGNITIVE DYSFUNCTION IN PROGRESSIVE MULTIPLE SCLEROSIS.

FIRST USE OF ALEMTUZUMAB IN BALO CONCENTRIC SCLEROSIS: A CASE REPORT.

A regenerative approach to the treatment of multiple sclerosis.

Multiple sclerosis: An old drug plays a new trick.

Read more »

Labels: 500 BEST PML STORIES & STUDIES, Ampyra, For Doctors, PML (Progressive Multifocal Leukoencephalopathy), sativex, Study, Tysabri

Clinical Trials Necessary to Approve a Copaxone Generic

(Posted By: Josi Creek)

Any generic of Teva’s blockbuster multiple sclerosis treatment Copaxone would need clinical trials to gain approval, the company says in response to speculation that the FDA might approve a generic Copaxone using the same criteria it applied to generic Lovenox. “In the case of Copaxone and other complex molecules, there are no acceptable … tests either in humans or animals that can be relied upon except for complete clinical tests, which reflect the clinical outcome in multiple sclerosis,” Teva CEO Shlomo Yanai said. 

Labels: Study

Aubagio (Teriflunomide) and Copaxone (Glatiramer Acetate) Combination Safe and Effective Against Relapsing-remitting Multiple Sclerosis

(Posted By: Josi Creek)

The current long-term therapies used to treat multiple sclerosis (MS) are administered intramuscularly or subcutaneously, producing local adverse effects at the sites of injection. Hence, the development of an orally administered drug would offer greater convenience and be more acceptable to patients. Teriflunomide is one of five such orally administered disease-modifying agents (used against rheumatoid arthritis) currently under investigation. Now, a Phase II trial conducted by researchers at the Mount Sinai School of Medicine reports teriflunomide to be safe and effective when used in conjunction with glatiramer acetate for the treatment of relapsing-remitting multiple sclerosis (RRMS).

Labels: Aubagio, Study

Breakthrough Finding from Israel may Lead to Earlier Diagnosis Multiple Sclerosis

(Posted By: Josi Creek)


A breakthrough finding from Israel may lead to earlier diagnosis, more effective intervention, and perhaps even a cure for the autoimmune disease multiple sclerosis.

"Those who will develop MS will show a different blood signature from those who will not," Prof. Anat Achiron, director of the Multiple Sclerosis Center at Sheba Medical Center.

Read more »

Labels: Study

New Formulation of Copaxone:Teva Announces Positive Study Results

(Posted By: Josi Creek)

Significantly less pain and fewer injection site reactions were reported by patients receiving the new lower volume injection

Read more »

Labels: Study